XTL Biopharmaceuticals Ltd News - XTLB | ADVFN

Register to chat with like-minded investors on our interactive forums.

Get Started

Home
Investing
Stocks
USA
NASDAQ
XTL Biopharmaceuticals Ltd (XTLB)
XTL Biopharmaceuticals Ltd (XTLB) News

XTL Biopharmaceuticals Ltd (XTLB)

2.44

0.00

(0.00%)

At close: April 19 4:00PM

Delayed by 15 minutes

2.44

0.00

( 0.00% )

After Hours: 4:41PM

Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

XTL To Aquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI companydeveloping and powering an IP...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form...

Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K ...

Annual and Transition Report (foreign Private Issuer) (20-f)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

1
Next

glenn1919

glenn1919 2 weeks ago

XTLB......................................https://stockcharts.com/h-sc/ui?s=XTLB&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 3 weeks ago

Monksdream

Monksdream 4 weeks ago

Pedro2004

Pedro2004 4 weeks ago

Schwabb won't let me short companies likes this.

Pedro2004

Pedro2004 4 weeks ago

Nice little pump and dump today.

Pedro2004

Pedro2004 4 weeks ago

Another scam Israeli company.

Monksdream

Monksdream 4 weeks ago

Zardiw

Zardiw 4 weeks ago

$XTLB Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:

Z

Monksdream

Monksdream 1 month ago

XTLB new 52 week hi

Awl416

Awl416 1 month ago

XTL To Aquire The Social Proxy

stock1ace1

stock1ace1 1 month ago

27k vol unusual vol 2 days before run looks like some insiders knew the news was coming …

stock1ace1

stock1ace1 3 years ago

trendzone

trendzone 3 years ago

Halted shorts about to get ripped apart

stock1ace1

stock1ace1 3 years ago

News Watch Latest Pr Co Seeking Partnership/Merger

The Company is expanding its IP portfolio surrounding hCDR1 and has decided, at this time, to explore cooperation with a strategic partner in order to execute its clinical trials. In parallel, the Company will look to expand and identify additional assets to add to XTL’s portfolio.

alchemytrader

alchemytrader 3 years ago

stock1ace1

stock1ace1 3 years ago

$3.62 Macd crossover #bullish -> https://stockcharts.com/h-sc/ui?s=Xtlb

stock1ace1

stock1ace1 3 years ago

XTLb is continually looking for late stage products to in-license or acquire. In addition, we are pursuing partnerships for the development and marketing of our products internationally. If your company has interest in discussing a potential business collaboration with XTL, please contact our business development department at: bd@xtlbio.com or call us at +972 9 955 7080.

stock1ace1

stock1ace1 3 years ago

Company is seeking merger / partnership The Company is expanding its IP portfolio surrounding hCDR1 and has decided, at this time, to explore cooperation with a strategic partner in order to execute its clinical trials. In parallel, the Company will look to expand and identify additional assets to add to XTL’s portfolio.

ClayTrader

ClayTrader 3 years ago

* * $XTLB Video Chart 03-05-2021 * *

Link to Video - click here to watch the technical chart video

odds_are

odds_are 3 years ago

Thanks for the link. Other boards seem to be clueless as to why the sharp increase in price.$XTLB

AlphaStockNews

AlphaStockNews 3 years ago

$XTLB is screaming for the top after a recent report shows massive growth in the company's target market. This is a clear acquisition target! https://cnafinance.com/xtlb-stock-xtl-biopharmaceuticals-is-rocketing/

Awl416

Awl416 3 years ago

wesley_

wesley_ 4 years ago

PennyStock Alert

PennyStock Alert 5 years ago

http://barchart.com/quotes/stocks/XTLBY

ClayTrader

ClayTrader 6 years ago

* * $XTLB Video Chart 05-07-18 * *

Link to Video - click here to watch the technical chart video

Joecanada13

Joecanada13 6 years ago

Tdash

Tdash 7 years ago

Awl416

Awl416 7 years ago

PAC

PAC 7 years ago

What was the volume AH yesterday?

europtiger

europtiger 7 years ago

There is some 3,50 Gifts

europtiger

europtiger 7 years ago

stocktrademan

stocktrademan 8 years ago

XTLB bullish 1.22

Yo-Yo

Yo-Yo 8 years ago

Whose driving this bus today, any catalyst here? GLTA!!!

fortunebuilder1959

fortunebuilder1959 10 years ago

Will def have this on my radar; ready to jump in with any momentum....

Arizzle

Arizzle 10 years ago

I must have missed the pump too

marcusjtrader

marcusjtrader 10 years ago

XTLB is a clear pump and dump based on charting. The company hasn't had any news in over a month. Claim your shares to short now.

Arizzle

Arizzle 10 years ago

jcseattle

jcseattle 10 years ago

http://finance.yahoo.com/news/xtl-biopharmaceuticals-further-strengthens-team-120000879.html

jcseattle

jcseattle 10 years ago

(XTLB) Very good time to short it.

AntiOne

AntiOne 10 years ago

Boom...another pick skyrocket from BackPackOfStock

Tradescott818

Tradescott818 10 years ago

javier1973

javier1973 10 years ago

Tradescott818

Tradescott818 10 years ago

Wowwowowowowowowoowow

AntiOne

AntiOne 10 years ago

Just picked a few shares....heard rumblings

surf1944

surf1944 10 years ago

8:02AM XTL Biopharma announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, (XTLB) 2.73 : Co announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus.

Two placebo controlled Phase I trials and a placebo controlled Phase II trial were conducted by Teva Pharmaceutical (TEVA) which had previously in-licensed hCDR1 from Yeda. The Phase I and Phase II studies consisted of over 400 patients, demonstrating that hCDR1 is well tolerated by patients and has a favorable safety profile. The PRELUDE trial did not achieve its primary efficacy endpoint based on the SLEDAI scale, resulting in Teva returning the asset to Yeda. However, the PRELUDE trial showed encouraging results in its secondary clinical endpoint, the BILAG index, and, in fact, the 0.5 mg weekly dose showed a substantial effect. Multiple post-hoc analyses also showed impressive results for this dose using the BILAG index. Such dose will be the focus of the clinical development plan moving forward.

The FDA has since directed that the primary endpoint in future trials for Lupus therapies, including those for hCDR1, should be based on either the BILAG index or the SLE Responder Index. Given the FDA's recommendation and the positive findings from the PRELUDE trial, XTL intends to initiate a new Phase II clinical trial, which will include the 0.5 mg (and a 0.25 mg) weekly dose of hCDR1.

Renee

Renee 11 years ago

XTLBY changed to XTLB and uplisted to the Nasdaq NCM:

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/12/2013&mkt_ctg=NON-OTCBB

Renee

Renee 12 years ago

XTLBY: 1-10 R/S concurrent with a ratio change. The ADR Ratio will change from [ one(1) ADS: two (2) Ordinary Share] to a new ratio of [ one (1) ADS: twenty (20) Ordinary Share]. Holders of XTL BioPharmaceuticals will be required on a mandatory basis to surrender their Old ADSs to BNY Mellon in exchange for the New ADSs. ONly whole DRs will be distributed.

http://www.otcbb.com/asp/dailylist_detail.asp?d=10/03/2012&mkt_ctg=NON-OTCBB

Eugene_2009

Eugene_2009 12 years ago

Hello,
Is there more information over XTLBY?

Eugene_2009

Eugene_2009 12 years ago

http://barchart.com/quotes/stocks/XTLBY

paulbk

paulbk 12 years ago

Hello to you as well. Sounds like the adjustment has to be enough to ensure a Nasdaq listing which I guess means at least 5 dollars. Good luck to you.

XTL Biopharmaceuticals

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions